ZUPREME-4: Petrelintide Phase 3 trial (NCT07843485)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrolment
- 600
- estimated
- Start
- 30 Sep 2026 (estimated)
- Primary completion
- 20 Oct 2028 (estimated)
- Sponsor
- Hoffmann-La Roche
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Petrelintide | Experimental | Combination Product: Petrelintide | Not stated |
| Placebo | Placebo comparator | Combination Product: Placebo | Not stated |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage Change in Body Weight from Baseline | From Baseline to Week 64 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportion of Participants Achieving ≥ 5% Body Weight Loss from Baseline | From Baseline to Week 64 |
| Proportion of Participants Achieving ≥ 10% Body Weight Loss from Baseline | From Baseline to Week 64 |
| Proportion of Participants Achieving ≥ 15% Body Weight Loss from Baseline | From Baseline to Week 64 |
| Change from Baseline in Waist Circumference (cm) | From Baseline to Week 64 |
| Change from Baseline in Hemoglobin A1c (HbA1c) | From Baseline to Week 64 |
| Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQoL-Lite-CT) Physical Functioning Composite Score | From Baseline to Week 64 |
| Change from Baseline in Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score | From Baseline to Week 64 |
| Change from Baseline in Mean Daily Food Craving Score | From Baseline to Week 64 |
| Change from Baseline in Mean Daily Peak Hunger Score | From Baseline to Week 64 |
| Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) | From Baseline to Week 64 |
| Change from Baseline in Body Mass Index (BMI) (kg/m²) | From Baseline to Week 64 |
| Change from Baseline in Body Weight (kg) | From Baseline to Week 64 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.